Competing risks of death in younger and older postmenopausal breast cancer patients

Figure 1 Cumulative hazard of breast cancer and other cause mortality by natural logarithm of survival time.

Figure 2 Normal probability plot for natural logarithm of breast cancer survival time.

Figure 3 Breast cancer survival. A: Breast cancer survival by treatment: Experience for the two treatment arms, tamoxifen and tamoxifen + octreotide LAR overlay each other; B: Breast cancer survival by tumour size; C: Breast cancer survival by nodal status; D: Other cause mortality by treatment; E: Other cause mortality by age; F: Other cause mortality by body mass index.

Figure 4 Breast cancer standardized residuals vs time: The residuals indicate that the natural logarithm of survival times are consistently smaller than they are expected to be; there are explanatory factors for breast cancer-specific that are not included in this investigation.

Figure 5 Other cause standardized residuals vs time: The residuals indicate that the natural logarithm of survival times are consistently smaller than they are expected to be; there are explanatory factors for other cause that are not included in this investigation.